| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8513255 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(25 days from now) | |
| US7196086 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(25 days from now) | |
| USRE46791 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(25 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603384 | MERCK SHARP DOHME | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative |
Feb, 2033
(8 years from now) | |
Prevymis is owned by Merck Sharp Dohme.
Prevymis contains Letermovir.
Prevymis has a total of 4 drug patents out of which 0 drug patents have expired.
Prevymis was authorised for market use on 08 November, 2017.
Prevymis is available in tablet;oral, solution;intravenous dosage forms.
Drug patent challenges can be filed against Prevymis from 08 November, 2021.
The generics of Prevymis are possible to be released after 28 February, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-165) | Nov 08, 2024 |
| New Dosing Schedule(D-189) | Aug 02, 2026 |
| Orphan Drug Exclusivity(ODE-423) | Jun 05, 2030 |
| New Indication(I-916) | Jun 05, 2026 |
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2022 |
Drugs and Companies using LETERMOVIR ingredient
NCE-1 date: 08 November, 2021
Market Authorisation Date: 08 November, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS; TABLET;ORAL
More Information on Dosage
PREVYMIS family patents
